{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:21:02Z","timestamp":1788189662936,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40123-025-01204-0","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T10:30:10Z","timestamp":1752921010000},"page":"2197-2214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Faricimab in the Treatment of Exudative Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Italy: The FARIT Real World Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-2488","authenticated-orcid":false,"given":"Marco","family":"Lupidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-6480","authenticated-orcid":false,"given":"Cristiana","family":"Iaculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8682-6860","authenticated-orcid":false,"given":"Settimio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Sicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5760-5607","authenticated-orcid":false,"given":"Vittorio","family":"Pirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"1204_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0161-6420(94)31217-6","volume":"101","author":"SE Moss","year":"1994","unstructured":"Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061\u201370.","journal-title":"Ophthalmology"},{"key":"1204_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients. Ophthalmol Retin. 2020;4:19\u201330.","journal-title":"Ophthalmol Retin"},{"key":"1204_CR3","first-page":"S172","volume":"25","author":"NM Holekamp","year":"2019","unstructured":"Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Manag Care. 2019;25:S172\u201381.","journal-title":"Am J Manag Care"},{"key":"1204_CR4","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910362","volume":"11","author":"A Wolf","year":"2019","unstructured":"Wolf A, Langmann T. Anti-VEGF-A\/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study. EMBO Mol Med. 2019;11: e10362.","journal-title":"EMBO Mol Med"},{"key":"1204_CR5","volume-title":"Oxford textbook of endocrinology and diabetes","author":"JR MacKinnon","year":"2022","unstructured":"MacKinnon JR, Forrester JV. Diabetic retinopathy. In: Wass JAH, Shalet SM, editors. Oxford textbook of endocrinology and diabetes. Oxford: Oxford University Press; 2022."},{"key":"1204_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","volume":"33","author":"RP Gale","year":"2019","unstructured":"Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et\u00a0al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33:1\u201321.","journal-title":"Eye"},{"key":"1204_CR7","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et\u00a0al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"1204_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/cxo.12552","volume":"100","author":"E Liu","year":"2017","unstructured":"Liu E, Craig JE, Burdon K. Diabetic macular oedema: clinical risk factors and emerging genetic influences. Clin Exp Optom. 2017;100:569\u201376.","journal-title":"Clin Exp Optom"},{"key":"1204_CR9","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et\u00a0al. Prevalence of age-related macular degeneration in Europe. Ophthalmology. 2017;124:1753\u201363.","journal-title":"Ophthalmology"},{"key":"1204_CR10","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12325-017-0548-1","volume":"34","author":"N Dervenis","year":"2017","unstructured":"Dervenis N, Mikropoulou AM, Tranos P, Dervenis P. Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges. Adv Ther. 2017;34:1270\u201382.","journal-title":"Adv Ther"},{"key":"1204_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Gentile B, Chi GC, Mirt M, et\u00a0al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"key":"1204_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et\u00a0al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1204_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/eye.2016.18","volume":"30","author":"JM Baxter","year":"2016","unstructured":"Baxter JM, Fotheringham AJ, Foss AJE. Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (Lond). 2016;30:698\u2013704.","journal-title":"Eye (Lond)"},{"key":"1204_CR14","unstructured":"Vabysmo. Summary of product characteristics [Internet]. [cited 15 Feb. 2025]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf."},{"key":"1204_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab up to every 16\u00a0weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1204_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"1204_CR17","unstructured":"AIFA. Determinazione 20 marzo 2008 Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. [Internet]. Jan 2008. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2008\/03\/31\/08A02109\/sg."},{"key":"1204_CR18","unstructured":"German Society for Epidemiology. Recommendations for good epidemiologic practice [Internet]. 2008 [cited 26 Jun. 2023]. https:\/\/www.dgepi.de\/assets\/Leitlinien-und-Empfehlungen\/Recommendations-for-good-Epidemiologic-Practice.pdf."},{"key":"1204_CR19","unstructured":"ISPE. Guidelines for Good Pharmacoepidemiology Practices (GPP)\u2014International Society for Pharmacoepidemiology [Internet]. 2015 [cited 26 Jun. 2023]. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/."},{"key":"1204_CR20","first-page":"311","volume":"67","author":"N Holekamp","year":"2024","unstructured":"Holekamp N, Gentile B, Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Viola F, et\u00a0al. Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema. Ophthalmic Res. 2024;67:311\u201321.","journal-title":"Ophthalmic Res"},{"key":"1204_CR21","unstructured":"ISTAT. Rapporto annuale 2018. La situazione del Paese [Internet]. [cited 10 Mar. 2025]. https:\/\/www.istat.it\/storage\/rapporto-annuale\/2018\/Rapportoannuale2018.pdf."},{"key":"1204_CR22","unstructured":"ACI. Costi chilometrici [Internet]. [cited 10 Mar. 2025]. https:\/\/www.aci.it\/i-servizi\/servizi-online\/costi-chilometrici.html."},{"key":"1204_CR23","volume":"7","author":"A Avenali","year":"2020","unstructured":"Avenali A, Catalano G, Gregori M, Matteucci G. Rail versus bus local public transport services: a social cost comparison methodology. Transp Res Interdiscip Perspect. 2020;7: 100200.","journal-title":"Transp Res Interdiscip Perspect"},{"key":"1204_CR24","unstructured":"Comune di Milano. Servizio taxi e tariffe applicate [Internet]. Comune di Milano. [cited 10 Mar. 2025]. https:\/\/www.comune.milano.it\/aree-tematiche\/mobilita\/taxi."},{"key":"1204_CR25","unstructured":"CCNL-Contratti Collettivi Nazionali di Lavoro. Contratto Collettivo Nazionale di Lavoro Colf e Badanti [Internet]. [cited 10 Mar. 2025]. https:\/\/servizi2.inps.it\/docallegati\/Mig\/Allegati\/701Nuovo_CCNL_colf_badanti_Ebilcoba.pdf."},{"key":"1204_CR26","unstructured":"ISTAT. Multiscopo sulle famiglie: uso del tempo [Internet]. [cited 10 Mar. 2025]. https:\/\/www.istat.it\/microdati\/multiscopo-sulle-famiglie-uso-del-tempo\/."},{"key":"1204_CR27","doi-asserted-by":"crossref","unstructured":"Pradelli L, Ghetti G. A general model for the estimation of societal costs of lost production and informal care in Italy. Farmeconomia health economics and therapeutic pathways [Internet]. 2017 [cited 10 Mar. 2025];18. https:\/\/journals.seedmedicalpublishers.com\/index.php\/FE\/article\/view\/1278.","DOI":"10.7175\/fe.v18i1.1278"},{"key":"1204_CR28","doi-asserted-by":"crossref","unstructured":"No authors listed. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology. 1991;98:823\u201333.","DOI":"10.1016\/S0161-6420(13)38014-2"},{"key":"1204_CR29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.oret.2024.12.021","volume":"9","author":"MA Zarbin","year":"2025","unstructured":"Zarbin MA, Weng CY, London NJS, Koh AHC, Gallego-Pinazo R, Chaudhary V, et\u00a0al. Disease activity criteria impact dosing interval assignment in neovascular age-related macular degeneration trials. Ophthalmol Retin. 2025;9:404\u20137.","journal-title":"Ophthalmol Retin"},{"key":"1204_CR30","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41433-021-01702-y","volume":"36","author":"A Lotery","year":"2022","unstructured":"Lotery A, Clemens A, Tuli R, Xu X, Shimura M, Nardi M, et\u00a0al. Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. Eye (Lond). 2022;36:1656\u201361.","journal-title":"Eye (Lond)"},{"key":"1204_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen S-J, Kim JE, et\u00a0al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific ocular imaging society PCV workgroup. Ophthalmology. 2021;128:443\u201352.","journal-title":"Ophthalmology"},{"key":"1204_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M. Intravitreal faricimab for treatment na\u00efve patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retin Vitreous. 2024;10:70.","journal-title":"Int J Retin Vitreous"},{"key":"1204_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:83\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"1204_CR34","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et\u00a0al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13:2985\u201397.","journal-title":"Ophthalmol Ther"},{"key":"1204_CR35","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. OPTH. 2023;17:2201\u20138.","journal-title":"OPTH"},{"key":"1204_CR36","first-page":"447","volume":"114","author":"S Calabria","year":"2023","unstructured":"Calabria S, Ronconi G, Dondi L, Piccinni C, Pedrini A, Dondi L, et\u00a0al. La popolazione con degenerazione maculare neovascolare correlata all\u2019et\u00e0 trattata con anti-Vegf attraverso i dati amministrativi sanitari. Recenti Prog Med. 2023;114:447\u201361.","journal-title":"Recenti Prog Med"},{"key":"1204_CR37","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/ijerph19052548","volume":"19","author":"V Perrone","year":"2022","unstructured":"Perrone V, Dovizio M, Veronesi C, Citraro R, De Francesco A, Dell\u2019Orco S, et\u00a0al. Retrospective analysis of the pharmaco-utilization of VEGF inhibitors and health care costs among patients with wet age-related macular degeneration and other ocular diseases in Italy. IJERPH. 2022;19:2548.","journal-title":"IJERPH"},{"key":"1204_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1120672120915685","volume":"30","author":"T Avitabile","year":"2020","unstructured":"Avitabile T, Boscia F, Dell\u2019Erba A, Introini U, Lanzetta P, Locatelli P, et\u00a0al. Definition of indicators of appropriateness in the management of neovascular age-related macular degeneration: an expert opinion. Eur J Ophthalmol. 2020;30:795\u2013804.","journal-title":"Eur J Ophthalmol"},{"key":"1204_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/00002512-200825030-00007","volume":"25","author":"F Bandello","year":"2008","unstructured":"Bandello F, Augustin A, Sahel J-A, Benhaddi H, Negrini C, Hieke K, et\u00a0al. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy. Drugs Aging. 2008;25:255\u201368.","journal-title":"Drugs Aging"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01204-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01204-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01204-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:43:30Z","timestamp":1757256210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01204-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01204-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marco Lupidi\u2014Abbvie, Apellis, Bayer, Novartis, Heidelberg Engineering, Lumibrid, and Roche. Cristiana Iaculli\u2014Roche and Bayer. Luisa Marco, Emilia Sicari, and Giulia Villa are Roche employees. Settimio Rossi and Vittorio Pirani declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The research and data handling were conducted in compliance with the national legislation on observational studies [], the Principles of Good Practice [, ], and the tenets of the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Regione Marche-CERM (protocol no. 2024\/29), which served as the coordinating committee, and was subsequently approved by the ethics committees of all participating centers (details provided in Supplementary Material Table\u00a0). The study was also registered in the AIFA Observational Study Register (RSO) (study ID 1045). Written consent was obtained from all patients prior to enrollment and data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}